Zero Approved Drugs, $28M Profit: A Biotech Run by an Ex-Analyst
Xinnuowei Pharma turned a profit before a single drug reached the market — by licensing its pipeline to Astellas and other major pharma comp
Xinnuowei Pharma turned a profit before a single drug reached the market — by licensing its pipeline to Astellas and other major pharma comp
Changjin Photonics surged 1,510% on its Shanghai IPO day — an all-time A-share record — while its founder was still a full-time university p